Literature DB >> 29928372

Comparative analysis of the surgical treatment results for multiple myeloma bone disease of the spine and the long bone/soft tissue.

Jiangtao Shen1, Xinru Du2, Lingxiu Zhao3, Hui Luo2, Ziyu Xu2.   

Abstract

The present retrospective study was designed to compare the pain relief, surgery duration, life quality, survival time and relative prognostic factors in multiple myeloma (MM) bone disease patients with different surgical sites. A total of 65 cases were enrolled and divided into two groups. Group A included patients with lesions located in the spine, while Group B included patients with lesions located in the long bone or soft tissue. Pain relief was measured by the visual analogue scale (VAS), neurological impairment was determined according to Frankel classification, and survival was assessed by the Kaplan-Meier method. Cox regression analysis was also used to estimate the effect of factors on the prediction of survival. The hospitalization time, preoperative duration of symptoms, method of surgery, complications, recurrence and survival time were evaluated and compared retrospectively. Pain relief and improvement of life quality were observed in all the patients in groups A and B. No significant differences were detected for the majority of parameters compared between groups A and B, with the exception of the surgery duration, as well as the postoperative VAS score at 1 and 6 months after surgery. The multivariate Cox regression analysis revealed several risk factors significantly associated with survival, including the preoperative VAS score, postoperative chemotherapy, prothrombin time activity (PTA), albumin, lactate dehydrogenase and urine protein level. In conclusion, surgical treatment was an effective therapeutic method in patients with MM. Postoperative analgesic use should be individualized according to the different surgical sites and postoperative periods. Furthermore, preoperative pain, PTA, albumin, urine protein level and postoperative chemotherapy are associated with prognosis.

Entities:  

Keywords:  comparative analysis; different surgical sites; multiple myeloma; surgical treatment

Year:  2018        PMID: 29928372      PMCID: PMC6004680          DOI: 10.3892/ol.2018.8559

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  45 in total

1.  Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression.

Authors:  Dirk Rades; Stefan Huttenlocher; Juergen Dunst; Amira Bajrovic; Johann H Karstens; Volker Rudat; Steven E Schild
Journal:  J Clin Oncol       Date:  2010-07-06       Impact factor: 44.544

2.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

3.  Kyphoplasty in patients with multiple myeloma a retrospective comparative pilot study.

Authors:  Christian Kasperk; Andreas Haas; Jens Hillengass; Christel Weiss; Kai Neben; Hartmut Goldschmidt; Ulrike Sommer; Peter Nawroth; Peter-Jürgen Meeder; Bernd Wiedenhöfer; Gerhard Schmidmaier; Michael Tanner; Dirk Neuhof; Gerd Nöldge; Ingo A Grafe
Journal:  J Surg Oncol       Date:  2011-09-29       Impact factor: 3.454

4.  Palliative radiotherapy in plasma cell myeloma.

Authors:  I A Adamietz; C Schöber; R W Schulte; D Peest; K Renner
Journal:  Radiother Oncol       Date:  1991-02       Impact factor: 6.280

5.  Survival, complications and outcome in 282 patients operated for neurological deficit due to thoracic or lumbar spinal metastases.

Authors:  Karl-Ake Jansson; Henrik C F Bauer
Journal:  Eur Spine J       Date:  2005-03-03       Impact factor: 3.134

6.  Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.

Authors:  R Lahtinen; M Laakso; I Palva; P Virkkunen; I Elomaa
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

Review 7.  The pathogenesis of the bone disease of multiple myeloma.

Authors:  Claire M Edwards; Junling Zhuang; Gregory R Mundy
Journal:  Bone       Date:  2008-02-21       Impact factor: 4.398

8.  Anterior decompression and stabilization of the spine as a treatment for vertebral collapse and spinal cord compression from metastatic malignancy.

Authors:  K D Harrington
Journal:  Clin Orthop Relat Res       Date:  1988-08       Impact factor: 4.176

9.  Relapse of multiple myeloma presenting as extramedullary plasmacytomas in multiple organs.

Authors:  Murat Köse; Ersida Buraniqi; Timur Selçuk Akpinar; Seyit Mehmet Kayacan; Tufan Tükek
Journal:  Case Rep Hematol       Date:  2015-01-28

10.  Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.

Authors:  Gareth J Morgan; J Anthony Child; Walter M Gregory; Alex J Szubert; Kim Cocks; Sue E Bell; Nuria Navarro-Coy; Mark T Drayson; Roger G Owen; Sylvia Feyler; A John Ashcroft; Fiona M Ross; Jennifer Byrne; Huw Roddie; Claudius Rudin; Gordon Cook; Graham H Jackson; Ping Wu; Faith E Davies
Journal:  Lancet Oncol       Date:  2011-07-21       Impact factor: 41.316

View more
  4 in total

Review 1.  [Management of osseous complications in multiple myeloma].

Authors:  K Zarghooni; S Hopf; P Eysel
Journal:  Internist (Berl)       Date:  2019-01       Impact factor: 0.743

2.  Orthopedic Surgical Treatment and Perioperative Complications in Multiple Myeloma Bone Disease: Analysis of a Series (2009-2018).

Authors:  María Galán-Olleros; Javier Marco; David Oteo; Rafael Cristóbal-Bilbao; Elena Manrique; Roberto García-Maroto; Fernando Marco; Juan Luis Cebrián-Parra
Journal:  Ann Surg Oncol       Date:  2020-07-13       Impact factor: 5.344

3.  In vivo antitumor efficacy of 17-AAG loaded PMMA in a human multiple myeloma xenograft mouse model.

Authors:  Xiangjun Shi; Yanzhe Wei; Xingchen Yao; Boran Du; Xiaoguang Wu; Xiangyu Kong; Xinru Du
Journal:  Clin Exp Med       Date:  2022-01-06       Impact factor: 3.984

4.  The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma.

Authors:  Chuanying Geng; Guangzhong Yang; Huijuan Wang; Zhiyao Zhang; Huixing Zhou; Wenming Chen
Journal:  Biomed Res Int       Date:  2021-05-19       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.